Here is the most recent development concerning Ozempic vision loss and blindness: The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found Ozempic significantly increases the risk of type 2 … [Read more...]
Syfovre Claims: Vision Loss and Blindness: Law / Legal
Syfovre claims for vision loss and blindness involving retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the … [Read more...]
Syfovre Vision Side Effects Cases Reported at Ophthalmology Meeting
A Syfovre vision side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November. William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre vision side effects cases ranging from hemorrhagic occlusive vasculitis-type … [Read more...]
Syfovre Retinal Vasculitis Cases Warning Letter July 2023
The American Society of Retinal Specialists (ASRS) issued a warning letter about the Syfovre retinal vasculitis cases in patients who used this injection eye drug. Syfovre is a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Occlusive retinal vasculitis is a type of eye inflammation that blocks blood flow … [Read more...]
EzriCare Artificial Tears Case Reports Involving Vision Loss
A recent edition of the JAMA Ophthalmology medical journal presented two EzriCare Artificial Tears case reports about serious infection and vision loss associated with these over-the-counter (OTC) eye drops from Global Pharma. The two EzriCare Artificial Tears case reports are set forth in these March 2023 JAMA Ophthalmology medical journal … [Read more...]
Beovu Label Change: Novartis Adds Information, Increases Safety Warnings in February 2022
We had been watching for a second Beovu label change since May 2021, when Novartis stopped three Beovu clinical trials for safety reasons, and, at the same time, said it would update the Beovu drug label. Finally, in February 2022, Novartis added information and increased safety warnings about various Beovu eye-related side effects, such as retinal … [Read more...]